How We Work

BiologicalE Vaccines

Back

Print

CHALLENGE

Pentavalent vaccines are more expensive due to the lack of clarity around the demand.

PROGRAM STRATEGY

Seek innovative approaches to reduce the cost of procuring pentavalent vaccine distributed in developing countries. We wan to reach more children while reducing the incidence of diptheria, tetanus, pertussis, Haemophilus influenzae type b, and hepatitis B.

PARTNER

Biological E. Limited
Private biotechnology company manufacturing pharmaceuticals and vaccines

Foundation focus: Reduce the cost of pentavalent vaccine

INVESTMENT

Volume Guaranty to Biological E Limited
Date: February 2012
Co-investors: None
Associated funding: None

Visit Our Blog

Connect